BHCBausch Health Companies Inc.

Bausch Health Companies Inc. (NYSE: BHC) | Price: $8.32 | Today's Change: +19.71%

---

What Happened

Bausch Health filed an 8-K with the SEC on October 28, 2026, disclosing its third-quarter fiscal 2026 financial results (Items 2.02 and 9.01). The company reported quarterly revenue of $7.47 billion and net income of $269 million, representing a return to meaningful profitability at the bottom line. Operating income came in at $1.339 billion for the quarter, underscoring the strength of earnings generation at the core operating level.

---

Why It Matters

For investors, the key takeaway is that Bausch Health is generating substantial operating cash conversion potential, with operating income of $1.339 billion far exceeding net income of $269 million — the gap reflecting the company's well-documented heavy debt-servicing burden. That said, the net income figure itself marks a tangible positive shift: basic EPS of $0.73 and diluted EPS of $0.72 represent real earnings rather than losses, a signal the business is covering its cost structure.

The 8-K also references total revenues of $10.447 billion in the structured data, which likely reflects a trailing or year-to-date aggregate figure, as the quarterly contract revenue figure is reported at $7.47 billion. Investors should monitor the full financial statements filed as exhibits for precise period-by-period breakdowns.

The stock's +19.71% move on the day suggests the market is treating these results as a meaningful positive surprise, pushing shares closer to levels last seen prior to the company's ongoing restructuring and debt discussions.

---

Analysis

Bausch Health has long been defined as much by its capital structure as by its underlying business performance. These Q3 2026 results are a reminder that the underlying commercial operations — spanning branded pharmaceuticals and its Bausch + Lomb eye-health franchise — continue to generate substantial revenues and, critically, real operating income.

The $1.339 billion in operating income against $7.47 billion in quarterly revenue implies an operating margin in the high-teens percentage range, which is competitive for a diversified specialty pharma company. The translation of that operating income into only $269 million of net income points to the scale of interest and other below-the-line charges, which remain the central overhang on the equity story.

Key items to watch going forward:

• How management characterizes debt reduction progress or any restructuring milestones on the earnings call or in supplementary disclosures
• Whether the revenue trajectory of the Bausch + Lomb segment, if separately reported, shows continued organic growth
• Full cash flow statements, which are not captured in these XBRL facts but will be critical to assessing debt-service capacity
• Any forward guidance or updated full-year outlook provided alongside these results

This follows StockWatch's existing initiating coverage on BHC. Today's results and the stock's sharp reaction speak directly to the core thesis around operational resilience — further commentary can be found in that prior coverage.

---

Disclaimer

This report is a news and informational summary based solely on data contained in Bausch Health's SEC filing dated October 28, 2026, and structured XBRL data extracted from that filing. It does not constitute investment advice, a solicitation to buy or sell any security, or an equity research recommendation. Readers should conduct their own due diligence and consult a qualified financial adviser before making investment decisions. The stock price and daily change cited reflect market data at the time of writing and may have changed.

Existing Coverage

StockWatch has full coverage on BHC, published 2026-10-07. Read our Initiating Coverage →

Source

Filed with the SEC on 2026-10-28. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/885590/000088559026000121/bhc-20261028.htm